The Potential of Mesenchymal Stromal Stem Cells to Correct Immune and Metabolic Dysfunctions in Circulating Immune Cells During Sepsis: An Ex Vivo Pilot Study.
Key facts
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 51 people, planned
- Started
- Sept 2026
- Expected to end
- Dec 2028
- Type of study
- Observational
- Treatments tested
- Blood sample
- Record updated
- 10 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patient or authorized representative, informed and having given consent
- Age ≥ 18 years
- Patients admitted for sepsis defined by the association as:; Clinically or microbiologically documented infection; SOFA-2 score ≥ 2; Or +2 points if pre-existing organ dysfunction
- Complicated; ARDS (Berlin criteria (1)); Acute respiratory failure; AND Bilateral pulmonary opacities (X-ray or CT scan) with no evidence of predominant hydrostatic edema; AND PaO₂/FiO₂ ≤ 300 mmHg under invasive or non-invasive ventilation with PEEP ≥ 5 cmH₂O; or septic shock (2); Vasopressors required to maintain mean arterial pressure (MAP) ≥ 65 mmHg; AND arterial lactate > 2 mmol/L; AND despite adequate fluid resuscitation
- Blood sample may be collected within 72 hours of admission to the intensive care unit
Who cannot take part
- Known severe immunodeficiency prior to sepsis:; cytostatic chemotherapy within the previous 3 months,; previously known neutropenia < 500/mm³ (within the past month) not attributed to sepsis,; active hematologic malignancy currently undergoing treatment,; allogeneic bone marrow transplant < 1 year ago,; solid organ transplant receiving immunosuppressants; corticosteroid therapy ≥ 0.5 mg/kg/day of prednisone equivalent for > 3 weeks,; anti-TNF or anti-IL-6 biologic therapy within the past 3 months,; HIV infection with a detectable viral load while not on treatment; Secondary exclusion criteria :
- Individuals not enrolled in or not eligible for a social security program
- Individuals subject to a legal protection order
- Pregnant women, women in labor, or breastfeeding women
- A diagnosis of sepsis was ruled out following a comprehensive medical evaluation and/or an alternative diagnosis was identified that explains the elevated SOFA-2 score
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a life-threatening organ dysfunction caused by the host's dysregulated immune response to infection. It represents a major global public health challenge. A state of post-septic compensatory immunosuppression may contribute to excess mortality by promoting secondary infections, thereby prolonging the stay in the intensive care unit and increasing the risk of death.
Read full original descriptionShow less
New therapeutic strategies to complement antimicrobial treatments-which may correct sepsis-induced functional alterations in immune cells (such as endotoxin tolerance and reduced HLA-DR expression), partly mediated by metabolic abnormalities-are currently being investigated. Among these, mesenchymal stromal cells (MSCs) appear particularly promising. They are capable of reprogramming immune cells by redirecting certain metabolic pathways, notably improving mitochondrial function. MSCs generally have an anti-inflammatory effect in preclinical models of infection, particularly in the early phase of severe ventilated pneumonia, as illustrated by the animal model we have developed, and preliminary trials are currently underway in humans. The ability of CSMs to correct sepsis-induced immunosuppression has not yet been explored. Nevertheless, CSMs possess the ability to communicate with the inflammatory microenvironment in which they are found, conferring plasticity to their response.
We hypothesize that CSMs could correct certain immune and metabolic dysfunctions in circulating immune cells from patients with sepsis meeting severity criteria who are admitted to the intensive care unit.
Furthermore, priming (or prior stimulation) of CSMs could enable a more precise and personalized therapeutic approach, with the possibility of directing CSMs toward a pro-inflammatory (CSM1) or anti-inflammatory (CSM2) phenotype through prior incubation with specific agonists (LPS; IFN-γ/TNF, respectively) before their administration. Depending on the patient's immune status (pro-inflammatory or anti-inflammatory phase), such a personalized approach would optimize treatment with CSMs.
The group in the trial
- Patient with sepsis complicated by ARDS or septic shock
Treatment: Blood sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 September 2026